Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02866695
Recruitment Status : Completed
First Posted : August 15, 2016
Results First Posted : February 25, 2019
Last Update Posted : February 25, 2019
Sponsor:
Information provided by (Responsible Party):
Sarah Arron, University of California, San Francisco

Brief Summary:
This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney transplant recipients and 10 lung transplant recipients. The investigators have selected these two populations as the represent the spectrum of solid organ transplantation: kidney transplant recipients are the largest transplant population, but have lower levels of immunosuppression and skin cancer risk. Lung transplant recipients have the highest burden of skin cancer and actinic keratoses.

Condition or disease Intervention/treatment Phase
Actinic Keratosis Drug: ingenol mebutate gel 0.015% Phase 4

Detailed Description:

Actinic keratoses (AK) are patches of dysplastic keratinocytes arising in sun-damaged skin. These lesions are precursors to cutaneous squamous cell carcinoma (SCC), and are treated to prevent progression to SCC. First-line therapy for AK include cryotherapy and curettage, which target clinically visible lesions but do not address the subclinical lesions in the field of ultraviolet radiation damage. Field therapy includes topical chemotherapy, immunotherapy, and photodynamic therapy. Ingenol mebutate is the active compound found in Euphorbia peplus sap, and has been approved for treatment of AK in immunocompetent patients. Ingenol mebutate 0.015% is favored over other topical treatments for treatment of AK on the face due to the brief treatment course, high clearance rate, and resolution without sequelae.

Solid organ transplant recipients (OTR) have a high incidence of AK and high risk of developing SCC, and require frequent field therapy. In addition, OTR generally have a higher burden of AK and require treatment of a larger surface area than the 25 cm2 area labeled for ingenol mebutate 0.015%. The investigators plan to investigate the safety and efficacy of ingenol mebutate 0.015% in OTR, with a treatment area up to 100cm2.

This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney transplant recipients and 10 lung transplant recipients. The investigators have selected these two populations as the represent the spectrum of solid organ transplantation: kidney transplant recipients are the largest transplant population, but have lower levels of immunosuppression and skin cancer risk. Lung transplant recipients have the highest burden of skin cancer and actinic keratoses.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients
Actual Study Start Date : October 6, 2016
Actual Primary Completion Date : July 2, 2018
Actual Study Completion Date : July 2, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Open label treatment
All patients will be treated with ingenol mebutate gel 0.015%. There is no placebo or comparator for this study. The investigator will identify the patient's treatment area at Baseline, and provide a detailed application instruction sheet. The first dose will be applied in clinic under the supervision of the investigator.
Drug: ingenol mebutate gel 0.015%
ingenol mebutate gel 0.015% to be applied on treatment area
Other Name: Picato




Primary Outcome Measures :
  1. Number of Participants With Adverse Events [ Time Frame: From screening to Day 57 or study early termination if applicable ]
    To evaluate the safety of ingenol mebutate gel 0.015% on the face in solid organ transplant recipients


Secondary Outcome Measures :
  1. Number of Participants With a Reduction of Actinic Keratosis [ Time Frame: Day 57 (assessed at screening, day 1, day 29, day 57, and study early termination if applicable, clearance at day 57 reported) ]
    To evaluate the efficacy of ingenol mebutate for reduction of actinic keratoses on the face in organ transplant recipients.

  2. Participant's Local Skin Response Grading Scale [ Time Frame: Day 1, Day 4 (assessed at screening, day 1, day 4, day 29, day 57, and study early termination if applicable, results at day 1 and day 4 reported) ]
    To investigate the local skin response to ingenol mebutate in organ transplant recipients. Local skin reaction (LSR) will be graded by visual assessment on a 4 point scale where 0=none, 1=mild, 2=moderate, 3=severe. Each of the following four reactions will be graded: erythema, vesiculation/postulation, crusting/scabbing/erosion, and edema/swelling. A composite score will be calculated (range 0-16). A high LSR indicated a worse outcome. LSR assessment will be performed at days 1, 8, 29, and 84.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adults at least 18 years old.
  2. Subject must be a solid organ transplant recipient at least one year from the date of transplantation.
  3. Subjects must be in stable health as confirmed by medical history, per investigator judgement.
  4. Subjects must be able to read, sign, and understand the informed consent.
  5. Subjects have at least 4 and no more than 20 clinically typical (non-hyperkeratotic/hypertrophic), visible actinic keratoses in a treatment area of approximately 100cm2 on the face. Treatment areas will include a single cheek (nasofacial sulcus to tragus, malar cheekbone to jawline and avoiding the lower eyelid and mouth); the forehead (hairline to eyebrows, extending laterally to the root of the helix).
  6. Subject must be willing to forego any other treatments on the face, including cryotherapy, tanning bed use and excessive sun exposure while in the study.
  7. Subject is willing and able to participate in the study and to comply with all study requirements including concomitant medication and other treatment restrictions.
  8. If subject is a female of childbearing potential she must have a negative urine pregnancy test result prior to study treatment initiation and must agree to use an approved method of birth control while enrolled in the study.

Exclusion Criteria:

  1. Subjects with an unstable medical condition as deemed by the clinical investigator.
  2. Subjects with a history of bone marrow or stem cell transplantation.
  3. Subjects with non-melanoma skin cancer on the face.
  4. Subjects with hyperkeratotic or hypertrophic AKs.
  5. Subjects with any dermatologic disease in the treatment area that may be exacerbated by the treatment proposed or that might impair the evaluation of AKs.
  6. Women who are pregnant, lactating, or planning to become pregnant during the study period.
  7. Subjects who have previously been treated with ingenol mebutate in study area within the past 8 weeks.
  8. Subjects who have used any topical prescription medications for actinic keratosis on the study area within 8 weeks prior to study treatment initiation.
  9. Subjects who have used any topical prescription medications for other reason on the study area within 4 weeks prior to study treatment initiation.
  10. Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device on the study area within 30 days prior to study treatment initiation.
  11. Subjects with known hypersensitivity to Picato gel or any of the inactive ingredients: isopropyl alcohol, hydroxyethyl cellulose, citric acid monohydrate, sodium citrate, or benzyl alcohol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02866695


Locations
Layout table for location information
United States, California
UCSF Dermatology
San Francisco, California, United States, 94115
Sponsors and Collaborators
University of California, San Francisco
Investigators
Layout table for investigator information
Principal Investigator: Sarah Arron, MD, PhD University of California, San Francisco
  Study Documents (Full-Text)

Documents provided by Sarah Arron, University of California, San Francisco:

Layout table for additonal information
Responsible Party: Sarah Arron, Principal Investigator & Associate Professor of Dermatology in Residence, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT02866695     History of Changes
Other Study ID Numbers: Leo AK
First Posted: August 15, 2016    Key Record Dates
Results First Posted: February 25, 2019
Last Update Posted: February 25, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data may be shared with authorized representatives of the study sponsor LEO Pharma, Inc., The University of California, FDA

Keywords provided by Sarah Arron, University of California, San Francisco:
Actinic Keratosis
lung transplant
kidney transplant

Additional relevant MeSH terms:
Layout table for MeSH terms
Keratosis
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Neoplasms